-
Mashup Score: 1FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease - 7 hour(s) ago
The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease - 3 day(s) ago
The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
BREAKING🚨: @US_FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease #hematology #oncology https://t.co/HyGNLQ2Uqo https://t.co/LNTrX8h9XU
-
-
Mashup Score: 2Ryoncil Receives FDA Approval for Children With GVHD - 23 day(s) ago
This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
BREAKING: Ryoncil receives @US_FDA approval for children with GVHD, marking this the first mesenchymal stromal cell therapy approved by the FDA for this patient population. #hematology #oncology Read more here: https://t.co/2jCkcisd0U https://t.co/ijCyUpHtMe
-
-
Mashup Score: 5FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease - 23 day(s) ago
The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
BREAKING🚨: @US_FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease #hematology #oncology https://t.co/HyGNLQ2Uqo https://t.co/LNTrX8h9XU
-
-
Mashup Score: 2
The European Commission has approved crovalimab for adult and pediatric patients with paroxysmal nocturnal hemoglobinuria.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Crovalimab Earns Approval in Europe for Paroxysmal Nocturnal Hemoglobinuria #hematology #oncology https://t.co/FaAfsq8VwT
-
-
Mashup Score: 1913th Annual New Therapeutics in Hematology and Oncology: The Road to Personalized Medicine - Cedars-Sinai - Continuing Education (CE) - 5 month(s) ago
Cedars-Sinai, 13th Annual New Therapeutics in Hematology and Oncology: The Road to Personalized Medicine, 11/15/2024 2:00:00 PM – 11/16/2024 6:00:00 PM, This important educational activity will provide guidance to front-line and oncology clinicians, nurses, physicians, pharmacists, nurse practitioners, physician assistants and pharmacists, with the most current information available about new agents in oncology and translating of the latest research to their patients. The conference will cover drug and treatment updates with a focus on precision medicine, gynecological malignancies, hematologic malignancies, prostate, bladder cancer and GI malignancies. The conference features a comprehensive review of new drugs approved along with their mechanism of action, and a keynote lecture, Stand Up to Cancer focusing on developmental therapeutics. Next generation studies will also be addressed, and the conference will offer participants a session designed to provide insight into the latest adva
Source: cedars.cloud-cme.comCategories: General Medicine News, Hem/OncsTweet-
Join us for the @CedarsSinai 13th Annual New Therapeutics Symposium, a 2-day conf on latest advances in #hematology #oncology @ReckampK @DrHendifar @DrArsenOsipov @AGangiMD @OmidHamidMD Dr. Giuliano @BJRimelMD & more Nov 15-16, 2024 @SofitelLA Register https://t.co/6Zxpyca7s5 https://t.co/6ZhMZyJZR1
-
-
Mashup Score: 1FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD - 5 month(s) ago
The FDA has accepted the resubmission of a BLA for remestemcel-L in pediatric steroid-refractory acute graft-vs-host-disease.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD @US_FDA #hematology #oncology https://t.co/XKOAFNx60X
-
-
Mashup Score: 0
Iopofosine I 131 generated a major response rate of 56.4% in patients with relapsed/refractory Waldenström macroglobulinemia.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Iopofosine I 131 Meets MRR End Point in R/R Waldenström Macroglobulinemia #hematology #oncology https://t.co/hEwf6SP5OD
-
-
Mashup Score: 1FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD - 5 month(s) ago
The FDA has accepted the resubmission of a BLA for remestemcel-L in pediatric steroid-refractory acute graft-vs-host-disease.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD @US_FDA #hematology #oncology https://t.co/XKOAFNx60X
-
-
Mashup Score: 0
Iopofosine I 131 generated a major response rate of 56.4% in patients with relapsed/refractory Waldenström macroglobulinemia.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Iopofosine I 131 Meets MRR End Point in R/R Waldenström Macroglobulinemia #hematology #oncology https://t.co/hEwf6SP5OD
-
BREAKING🚨: @US_FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease #hematology #oncology https://t.co/HyGNLQ2Uqo https://t.co/LNTrX8h9XU